JPH05201866A - 配合製剤 - Google Patents

配合製剤

Info

Publication number
JPH05201866A
JPH05201866A JP4234294A JP23429492A JPH05201866A JP H05201866 A JPH05201866 A JP H05201866A JP 4234294 A JP4234294 A JP 4234294A JP 23429492 A JP23429492 A JP 23429492A JP H05201866 A JPH05201866 A JP H05201866A
Authority
JP
Japan
Prior art keywords
diltiazem
controlled release
formulation
spheroid
hydrochlorothiazide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP4234294A
Other languages
English (en)
Japanese (ja)
Inventor
Ian R Buxton
イアン・リチヤード・ブツクストン
Adrian Brown
エイドリアン・ブラウン
Helen Critchley
ヘレン・クリツチリー
Stewart T Leslie
スチユワート・トーマス・レスリー
Sandra T A Malkowska
サンドラ・テレス・アントワネツト・マルコウスカ
Derek A Prater
デレク・アラン・プラター
Ronald B Miller
ロナルド・ブラウン・ミラー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euro Celtique SA
Original Assignee
Euro Celtique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique SA filed Critical Euro Celtique SA
Publication of JPH05201866A publication Critical patent/JPH05201866A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP4234294A 1991-08-12 1992-08-10 配合製剤 Pending JPH05201866A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9117361.7 1991-08-12
GB919117361A GB9117361D0 (en) 1991-08-12 1991-08-12 Oral dosage form

Publications (1)

Publication Number Publication Date
JPH05201866A true JPH05201866A (ja) 1993-08-10

Family

ID=10699854

Family Applications (1)

Application Number Title Priority Date Filing Date
JP4234294A Pending JPH05201866A (ja) 1991-08-12 1992-08-10 配合製剤

Country Status (14)

Country Link
US (1) US5508044A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0527638A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPH05201866A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR930003905A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1069191A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU658209B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2075355A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI923581L (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB9117361D0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL102777A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (2) IN173839B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO300797B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (1) PH30666A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (2) ZA926020B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08143450A (ja) * 1994-11-14 1996-06-04 Taiyo Yakuhin Kogyo Kk 徐放化製剤
JP2004510812A (ja) * 2000-10-13 2004-04-08 ユーロセルティック　ソシエテ　アノニム 遅延放出医薬製剤
JP2012525444A (ja) * 2009-05-01 2012-10-22 アプタリス ファーマテック インコーポレイテッド 高および低用量薬物の組み合わせを含む口腔内崩壊錠組成物

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301220D0 (sv) * 1993-04-14 1993-04-14 Kabi Pharmacia Ab Manufacturing matrices
US5834024A (en) * 1995-01-05 1998-11-10 Fh Faulding & Co. Limited Controlled absorption diltiazem pharmaceutical formulation
CN1103592C (zh) * 1996-05-22 2003-03-26 永光制药有限公司 含有2－(苯基亚氨基)－3－苯基－1,3－全氢噻嗪的药物组合物及其应用和制备方法
US6074669A (en) * 1997-01-20 2000-06-13 Ranbaxy Laboratories Limited Controlled drug delivery system for diltiazem
FR2771291B1 (fr) * 1997-11-21 2000-02-25 Ethypharm Lab Prod Ethiques Spheroides, procede de preparation et compositions pharmaceutiques
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
ES2264226T3 (es) 1997-12-22 2006-12-16 Euro-Celtique S.A. Forma farmaceutica de dosificacion oral que comprende una combinacion de un agonista opioide y naltrexona.
US6524620B2 (en) 1998-07-20 2003-02-25 Andrx Pharmaceuticals, Inc. Diltiazem controlled release formulation and method of manufacture
US6039979A (en) * 1999-01-13 2000-03-21 Laboratoires Prographarm Multiparticulate pharmaceutical form with programmed and pulsed release and process for its preparation
FR2794646B1 (fr) * 1999-06-09 2001-09-21 Ethypharm Lab Prod Ethiques Microgranules de sulfate de morphine, procede de preparation et composition les contenant
US6569456B2 (en) * 2000-01-13 2003-05-27 Osmotica Corp. Osmotic device containing diltiazem and an ACE inhibitor or diuretic
GB0007419D0 (en) * 2000-03-27 2000-05-17 Smithkline Beecham Gmbh Composition
ES2361148T3 (es) 2001-05-11 2011-06-14 Endo Pharmaceuticals Inc. Forma de dosificación de opioides de liberación controlada resistente al abuso.
EP2311438A1 (en) 2002-04-05 2011-04-20 Euro-Celtique S.A. Matrix for sustained, invariant and independent release of active compounds
US20040005358A1 (en) * 2002-04-23 2004-01-08 Slugg Peter H. Modified-release vasopeptidase inhibitor formulation, combinations and method
US8802139B2 (en) 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
SI21637A (sl) * 2003-12-23 2005-06-30 LEK farmacevtska dru�ba d.d. Farmacevtska oblika z nadzorovanim sproščanjem
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
EP1809260B1 (en) * 2004-11-08 2013-11-27 Rubicon Research Private Limited Aqueous pharmaceutical coating
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
CA2648280C (en) * 2006-04-03 2014-03-11 Isa Odidi Controlled release delivery device comprising an organosol coat
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
EP2049087A2 (en) * 2006-07-21 2009-04-22 LAB International SRL Hydrophilic abuse deterrent delivery system
CA2703365A1 (en) * 2007-10-25 2009-04-30 Yuka Yamanouchi Nifedipine-containing press coated tablet and method of preparing the same
UY32487A (es) 2009-03-10 2010-06-30 Euro Celtique Sa Composiciones farmacéuticas de liberación inmediata comprendiendo oxicodona y naloxona
GB201003731D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
GB201003734D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
GB201003766D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Pulsatile drug release
WO2015011189A1 (en) 2013-07-23 2015-01-29 Euro-Celtique S.A. A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK152744C (da) * 1982-08-13 1988-10-31 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk peroralt polydepotpraeparat
IE56999B1 (en) * 1983-12-22 1992-03-11 Elan Corp Plc Pharmaceutical formulation
US4728512A (en) * 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
IT1200217B (it) * 1986-09-30 1989-01-05 Valducci Roberto Membrana per uso farmaceutico ed industriale
CA1323833C (en) * 1987-04-28 1993-11-02 Yatindra M. Joshi Pharmaceutical compositions in the form of beadlets and method
IL88083A (en) * 1987-11-06 1992-11-15 Tanabe Seiyaku Co Controlled release pharmaceutical dosage form and its preparation
FI101344B (fi) * 1988-03-31 1998-06-15 Tanabe Seiyaku Co Menetelmä valmistaa valmiste, josta kontrolloidusti vapautuu farmaseut tisesti aktiivista ainetta
JPH0674206B2 (ja) * 1989-12-28 1994-09-21 田辺製薬株式会社 放出制御型製剤およびその製法
US5156850A (en) * 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery
DK0565634T3 (da) * 1990-12-14 1999-09-27 Smithkline Beecham Corp Angiotensin-II-receptorblokkersammensætninger
US5286497A (en) * 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08143450A (ja) * 1994-11-14 1996-06-04 Taiyo Yakuhin Kogyo Kk 徐放化製剤
JP2004510812A (ja) * 2000-10-13 2004-04-08 ユーロセルティック　ソシエテ　アノニム 遅延放出医薬製剤
JP2012525444A (ja) * 2009-05-01 2012-10-22 アプタリス ファーマテック インコーポレイテッド 高および低用量薬物の組み合わせを含む口腔内崩壊錠組成物

Also Published As

Publication number Publication date
ZA926020B (en) 1993-03-10
CN1069191A (zh) 1993-02-24
NO300797B1 (no) 1997-07-28
IL102777A0 (en) 1993-01-31
FI923581A0 (fi) 1992-08-11
EP0527638A1 (en) 1993-02-17
AU2087992A (en) 1993-02-18
AU658209B2 (en) 1995-04-06
KR930003905A (ko) 1993-03-22
US5508044A (en) 1996-04-16
NO923127D0 (no) 1992-08-11
NO923127L (no) 1993-02-15
FI923581A7 (fi) 1993-02-13
PH30666A (en) 1997-09-16
CA2075355A1 (en) 1993-02-13
IL102777A (en) 1996-05-14
GB9117361D0 (en) 1991-09-25
IN173847B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1994-07-23
IN173839B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1994-07-23
FI923581L (fi) 1993-02-13
ZA926019B (en) 1993-03-10

Similar Documents

Publication Publication Date Title
JPH05201866A (ja) 配合製剤
JP3019235B2 (ja) スフェロイド製剤
JP4637338B2 (ja) シロスタゾール有核錠
KR100348585B1 (ko) 다리페나신을함유하는약학제제
JP3140764B2 (ja) ミノサイクリンの脈動性１日１回放出系
RU2161956C2 (ru) Трехфазная фармацевтическая форма с постоянным и регулируемым высвобождением аморфного активного ингредиента для одноразового применения в сутки
CA2704646C (en) Sustained-release tablets with hydromorphone
US20090124702A1 (en) Pharmaceutical Compositions of Metformin
WO2009025859A1 (en) Paliperidone sustained release formulation
ZA200101485B (en) Multiple unit controlled food effect-independent release pharmaceutical preparations and method for preparing the same.
JP2009504795A (ja) １−（４−クロロアニリノ）−４−（４−ピリジルメチル）フタラジンおよびｐＨ調整剤を含む固体医薬組成物
WO2021111419A1 (en) Modified release pharmaceutical compositions of riociguat
JP2001517625A (ja) 活性成分放出制御薬物製剤
JP5105684B2 (ja) 持続性医薬製剤
TWI823471B (zh) 沙庫巴曲纈沙坦鈉緩釋組合物、其製備方法及應用
HRP970004A2 (en) Pharmaceutically controlled release of beads comprising furosemide and a formulation containing said controlled release beads
GB2258810A (en) Pharmaceutical combination formulation of diltiazem and hydrochlorothiazide
JP3007387B2 (ja) 徐放性製剤用基剤粉末
AU6224699A (en) Taste masking coating compositions
JPH024575B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB2258613A (en) Pharmaceutical diltiazem spheroid formulation
WO2009047800A2 (en) Oral controlled release composition of carvedilol
JP2008115083A (ja) 塩酸トラマドール含有コーティング顆粒
KR20040045485A (ko) 항경련제가 간격을 두고 배치된 약물전달계